Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bottom line to get the share price moving upwards and big is dependent on Lympro partnership. If the partner is a big key player I expect a huge move upwards especially if the partner is a big pharma then it will take off like a rocket. Investors should be patient just for that announcement alone!
Of course it will be I don't know how much more of a hint the CEO could have given lol. HINT HINT we found a partner for LYMPRO just finishing up deal...........hello lol. Good for AMBS!
They found partner for Lympro CEO mentioned at presentation, just finishing up the deal! Nice!
Presentation should start in one minute now! Get ready folks!
SA article on SYN "Why I'm Short Synthetic Biologics After Phase II Relapsing-Remitting MS Data" http://seekingalpha.com/article/2226563-why-im-short-synthetic-biologics-after-phase-ii-relapsing-remitting-ms-data
your guess is as good as mine!
mid year 2014 update on phase 2 hypertrophic scar as mentioned by CEO we should see how RXI-109 works on hypertrophic scars within next 2 months probably.
I think you might be right about the break out!
Right now $12.5 million but that's enough for the anti scarring compound for awhile. The ophtalmology pipeline is being funded by the private deal with Lincoln Capital.
Very good article talking about today's Inovio news "Inovio’s Not Done Adding To Its Pipeline Quite Yet" http://www.biotechpicklist.com/inovios-not-done-adding-to-its-pipeline-quite-yet/
The problem is the news wasn't posted to yahoo finance site. Not showing the brand new news! It should be posted on there but it is not!
So from that quote I'm inclined to see that AMBS is attempting to spin off the diagnostic portion as a standalone company. Will this be more beneficial for shareholders? I guess it does separate the division risk with the clinical research risk so that's a positive.
New SA instablog article out on Inovio " Going Long On Inovio Ahead Of Phase 2 Cervical Dysplasia Data Readout"
http://seekingalpha.com/instablog/1058124-long-term-bio/2867953-going-long-on-inovio-ahead-of-phase-2-cervical-dysplasia-data-readout
H.C. Wainwright has initiated coverage and started Rxi Pharmaceuticals at a "Buy" with a $9 price target
http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Starts+RXi+Pharmaceuticals+%28RXII%29+at+Buy%2C+PT+%249/9442464.html?si_client=st
depends if the phase 2 hypertrophic scar results are good 2 to 3 years maybe less if we get lucky like ICPT did. Too hard to predict like I said depends on the results we see.
That $200 per share + is just for the anti scarring. If you add in Liver fibrosis and other eye indications you are looking at a higher share price.
if Phase 2 RXI-109 is successful you can account for $2.5 billion dollar to $5 billion dollar opportunity so you do the math. We could be looking at $200 per share +
Wrote instablog SA article on Rxi-109 let me know what you think " Rxi Pharmaceutical's RXI-109 Does The Impossible Once Again!"
http://seekingalpha.com/instablog/1058124-long-term-bio/2885423-rxi-pharmaceuticals-rximinus-109-does-the-impossible-once-again
Don't know why it sold off on this news. Today's news used RXI-109 in retina scarring in Monkeys but the reason for the big pop was a surprise RXi didn't know would happen. The cornea also was improved in scarring as a bonus. These results today along with the phase 1 of RXI-109 pretty much validate the sd-rxRNA platform IMO bring on those phase 2 hypertrophic scar results.
If he truly believes in the company and thinks it is going to recover based off of the results that failed the primary endpoint mind you why would he dump 5 million shares now? Why not wait till the share price recovers? Nobody sells on the bottom unless they don't believe the stock will rise again.
Can you blame the guy? The primary endpoint of the study failed! Instead of management passing it off as positive preliminary results they should have been straight with their shareholders and said "hey the trial failed". They tried to spin the results and I'm sure that didn't sit well with Steve Kanzer so he sold 5 million shares.
As I have told many here the news today and other data will give us small pops like this but the big move will come from finding out who the partner with Lympro is? and the launch of Lympro itself! Those 2 catalysts IMO will move the stock in bigger ways.
I know it sucks to wait but MANF study data will come when it pours in. In the meantime though the company is making the right decision with advancing Lympro first. With Lympro the company can make millions of dollars early while under CLIA, while at the same time building up the therapeutic pipeline MANF etc. so management knows what they are doing, you have to put things into perspective.
Under CLIA with some revenue AMBS may not even have to dilute shareholders any more. It's a win win situation for the company and for shareholders. So Lympro as first priority is a wise decision. MANF test results will come as they are completed!
I told people yesterday something was fishy about the way they released the results. Today they showed more and thus the reason for the drop. Basically the P value p = .0306 was significant at 12 months but at the primary endpoint for FDA approval was not met. Primary endpoint needed to be at p <= .05 but instead at 24 months it was p = .1537. Company now believes it can lower the p value from .1537 all the way down to .05 or less by adding more patients in the study. it may or may not be possible but the bottom line is that the primary endpoint was not met thus the reason for the drop. Company should have not put out positive preliminary results should have been more honest with its shareholders IMO.
Biggest red flag is that CC stated that phase 2 was exploratory and 24 month primary endpoint was not supposed to be met. That apparently in phase 3 they will magically go from p value .1537 all the way down below p = .05 or less. They spun the results basically to make it look positive.
"In this Phase II study, women receiving oral Trimesta plus injectable Copaxone® demonstrated a statistically significant 47 percent decrease in annualized MS relapse rate in the first 12 months of treatment compared to women receiving placebo plus Copaxone (p=0.0306), and a 32 percent decrease in annualized relapse rate at 24 months (p=0.1527). Patients in both treatment arms demonstrated improved scores on the Expanded Disability Status Scale (EDSS) compared to baseline. Cognitive function test scores, as measured by the Paced Auditory Serial Addition Test (PASAT), in women receiving Trimesta plus Copaxone also improved compared to baseline and were significantly different from placebo plus Copaxone at 12 months."
I was looking at that as well because typically the p-value has to be under 0.1 to be stat significant . so the first 12 months was stat significant p = .0306 but the p value at 24 months was p = .1527 which is greater than 0.1 for stat significance. In essence the p value failed to be below stat significant threshold which means the primary endpoint of the study failed.
Okay so the company says positive preliminary results for phase 2. My main question is which might be cleared up tomorrow why don't they let their shareholders know the full results?
For instance:
1. What is the final p value in the study?
2. Why did it not list whether the primary endpoint was met or not met?
3. Why did it not list if the secondary endpoints were met or not met?
To me until they show all results it just seems fishy to me. also why did they say " preliminary" this concluded to me they have other data they are not sharing which irks me!
New SA article out for CYTK " Cytokinetics Fails Lou Gehrig's Trial But Still Holds Value With Cardiac Drug" http://seekingalpha.com/article/2174513-cytokinetics-fails-lou-gehrigs-trial-but-still-holds-value-with-cardiac-drug
Yes I am pretty fast on these things when it comes to RXII
news from RXI pharmaceuticals start of phase 2a keloid trial! http://finance.yahoo.com/news/rxi-pharmaceuticals-announces-initiation-phase-170300987.html
I agree since Jansen is a division of Johnson and Johnson. Good stuff coming down the pipe.
Good to see some data on Phenoguard on a new family path! More good things to come!
Amarantus news this Morning on Phenoguard presentation Data http://finance.yahoo.com/news/amarantus-cso-present-phenoguard-data-123000082.html
"RXi Pharmaceuticals to Present at ARVO 2014 Annual Meeting"
http://finance.yahoo.com/news/rxi-pharmaceuticals-present-arvo-2014-110200726.html
Here is an additional website with info on Rxi that talks about the company http://www.biotechpicklist.com/biotechpicklist/rxii-rxi-pharmaceuticals/
The best part about this is that Rxi will present an update on Retinoblastoma for what gene is being targeted.
Thanks Warp for the audio files: Key takeaways from the conference call that I liked: (obviously there are many but what I liked I will list)
1. There is soon to be a contract for Amarantus to move in to a manufacturing facility coming up I'm surprised not many mentioned this unless I missed it somewhere
2. Amarantus CEO has his father presenting at a conference next week about Phenoguard which can be a new protein family (meaning an increased portfolio position like MANF) which would increase value of the company.
3. Another thing I liked was that BD will finish lympro and hand it off to another company to commercialize. Depending what company it is this could be a very huge catalyst for the stock.
4. If MANF is successful in Wolfram's Syndrome it could be branched to type I and type II diabetes.
There are too many good things to list so I just chose some to list!
I told people here Lympro would be wanted with big interest from big pharma because 30% of patients enrolled in Alzheimers trials don't even have the disease. This skews the clinical data and ultimately garners a trial failure. With Lympro things can be changed!
WoW a lot of nice hires, I bet a lot of people don't know that some recent hires came from Novartis, Johnson and Johnson, and Pharmacyclics.
I don't think the conference will move it unless there are trial results that come out from the conference. Possibly maybe if other catalysts come out.
I don't mind all this selling gives me a chance to load up on more shares. People don't understand what the launch of Lympro will do for this company Thanks for all your shares if you are selling them.
Right now big pharmaceutical companies fail Alzheimers trials because 30% of the patients enrolled don't even have the disease which screws up the clinical trial data. With an accurate test (95%) certainty Lymrpo Big pharma will be dying to get their hands on this test. People don't understand the potential here!
Share price moves when an event happens. For instance I own RXII now trades at $4 per share and is expecting phase 2 results for anti scarring hypertrophic scars. Any positive news from that and that $4 stock turns into a $50 stock or $100 stock as anti scarring market is worth $2 to $5 billion dollars. The market is never rational rule #1, free lesson for you!